Molecular Inotropy
A Future Approach to the Treatment of Heart Failure?
William H. Barry, MD M aurice et al 1 recently reported that a global ventricular 10-fold overexpression of the ␤-2 adrenergic receptor, mediated by the intracoronary injection of an adenoviral vector, can be produced in the rabbit. This overexpression resulted in an increased maximum rate of change in left ventricular pressure, dp/dt max , both at baseline and in response to isoproterenol infusion at 6 days after transgene delivery, with the enhanced isoproterenol response persisting for up to 21 days. They concluded that genetic modulation to improve the function of the intact heart is feasible. In this issue of Circulation, del Monte et al 2 
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Early studies by Lindenmayer et al 4 suggested that the Ca 2ϩ uptake of isolated SR vesicles was impaired in failing human myocardium, and Grossman et al 5 found that the peak dp/dt of left ventricular pressure decline and the velocity of circumferential fiber lengthening were reduced in patients with congestive cardiomyopathy. Evidence that this impaired relaxation in the failing heart is due to abnormal Ca 2ϩ homeostasis was provided by Gwathmey et al. 6 Subsequently, a number of molecular studies in animal models and in human heart failure have suggested that during the process of hypertrophy and progression to failure, a fetal pattern of cardiac myocyte gene expression is activated; this pattern decreases the expression of the SR Ca 2ϩ ATPase and increases the expression of the Na ϩ /Ca 2ϩ exchanger. 8, 9 Functional studies have also suggested that the decreased activity of SR Ca 2ϩ
ATPase is an important contributor to the abnormal contraction of failing human myocardium. For example, Lindner et al 10 showed a reduced SR Ca 2ϩ content in myocytes from patients with terminal heart failure, and Hasenfuss et al 11 reported that the extent of the abnormality of the force-frequency relationship in the failing human myocardium could be correlated with the degree of reduction in the levels of the SR Ca 2ϩ ATPase protein. However, some studies in the failing human myocardium reported normal protein levels of SR Ca 2ϩ ATPase and normal rates of Ca 2ϩ uptake by vesicle preparations. 12 In addition, recent work by Dipla et al 13 in failing human ventricular myocytes demonstrated that increased function of the Na ϩ /Ca 2ϩ exchanger in failing cardiac myocytes, induced perhaps by an increased expression of the exchanger mentioned above and by the prolonged action potential duration that is seen in hypertrophied and failing myocardium, might produce excessive Ca 2ϩ influx on the exchanger during the prolonged action potential plateau. This prolonged influx of Ca 2ϩ could account for the secondary Ca 2ϩ transient hump, which was noted in the initial aequorin experiments of Gwathmey et al, 6 and could also contribute to the prolonged [Ca 2ϩ ] i transient and impaired relaxation. 13 Thus, some uncertainty exists regarding the central role of depressed SR Ca 2ϩ ATPase activity in producing impaired contraction and relaxation in heart failure.
It is important to note that other factors in hypertrophy and failure may influence the Ca 2ϩ sequestering function of the SR pump, independent of the level of SERCA2a expression. These include the leakiness of the SR for Ca 2ϩ , 14 the interaction of phospholamban with SR Ca 2ϩ ATPase 3 and, of course, the free energy available to drive the ATP-dependent SR Ca 2ϩ pump. Although the cellular changes associated with heart failure are complex and multifactorial, 15 this study by del Monte et al 2 provides strong additional support for the hypothesis that the impaired function of SR Ca 2ϩ ATPase plays an important role in the functional abnormalities observed.
Assuming that impaired Ca 2ϩ sequestration by the SR is involved in the progression to end-stage heart failure, 9 what is the evidence that gene therapy to increase the function of SR Ca 2ϩ ATPase may be effective in the treatment of heart failure?
Some very interesting experiments exist in transgenic mice that are relevant to this question. Crossing the Muscle LIM Protein Knockout (MLPKO) mouse, which develops a dilated cardiomyopathy, with a Bark-1 ct transgenic mouse, in which desensitization of the ␤ receptor (and presumably decreased phospholamban phosphorylation) is prevented, showed that the development of the heart failure phenotype can be prevented. 16 Also, enhancing SR Ca 2ϩ ATPase function by crossing the MLPKO with a phospholamban knockout animal can also prevent the development of the heart failure phenotype. 17 Although these data support the hypothesis that impaired function of the SR is important in the progression to end-stage failure, these murine experiments do not establish whether increased expression of the SR Ca 2ϩ ATPase can reverse heart failure once it has been established. The experiments performed by Maurice et al 1 and del Monte et al 2 suggest that this might be feasible in the intact human heart by using intracoronary adenovirus transfection of myocytes to increase the expression of SERCA2a.
This approach could face several potential problems, however. One is the question regarding whether increased expression of SR Ca 2ϩ ATPase might produce arrhythmias due to increased SR Ca 2ϩ loading. Ca 2ϩ overload with an increased diastolic [Ca 2ϩ ] i , produced by an increased Ca 2ϩ influx (via the L-type Ca 2ϩ channel or Na ϩ /Ca 2ϩ exchange), can produce delayed after depolarizations in the isolated cell, which will manifest as ventricular arrhythmias in the intact heart. 18 It seems that in the murine heart, increased function of SR Ca 2ϩ ATPase in vivo, which is induced directly by the increased expression of SERCA2a, 19 ] i , and does not induce arrhythmias. However, the degree of enhancement of SR function after adenoviral transfection of SERCA2a may be nonuniform in the intact heart. This could cause a nonuniformity of the [Ca 2ϩ ] i transient and a potential substrate for arrhythmias.
A second difficulty relates to the transient nature of adenoviral-transfected gene expression. Studies in which adenoviral vectors have been used to transfect genes into muscle cells have demonstrated that a cell-mediated immune response to the vector may limit expression to several weeks. 1, 20 Furthermore, humoral responses of neutralizing antibody to viral capsid proteins may prevent the readministration of the adenoviral vectors of the same type. Modifications of the adenovirus vector that may reduce host immune responses and the use of other viral vectors, such as the adeno-associated virus, 20 may also be helpful in allowing a longer term, stable expression of transfected genes in the muscle tissue.
As previous discussed, 9 it is possible that the impaired function of the SR produced by down-regulation of SR Ca 2ϩ expression may itself promote hypertrophy and, thus, cause a vicious cycle of progression to failure. In some situations, up-regulation of the SR Ca 2ϩ ATPase function by the techniques discussed above might stabilize or even improve cardiac function in vivo and, thus, provide a "molecular inotropic assist." Because impaired SR Ca 2ϩ ATPase function is undoubtedly not the only abnormality that contributes to contractile and electrophysiologic dysfunction in heart failure, 15 better definition of the other factors involved and their potential for correction by genetic techniques are important for future investigation.
